Emend and Rash maculo-papular - a phase IV clinical study of FDA data

Summary:

Rash maculo-papular is reported as a side effect among people who take Emend (aprepitant), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Solu-Medrol, and have Gastroesophageal reflux disease.

The phase IV clinical study analyzes which people have Rash maculo-papular when taking Emend. It is created by eHealthMe based on reports of 13,708 people who have side effects when taking Emend from the FDA, and is updated regularly.

What is Emend?

Emend has active ingredients of aprepitant. It is often used in nausea. eHealthMe is studying from 13,741 Emend users. Check the latest studies of Emend.

What is Rash maculo-papular?

Rash maculo-papular (red area on the skin that is covered with small confluent bumps) is found to be associated with 1,245 drugs and 1,534 conditions by eHealthMe. Check the latest studies of Rash maculo-papular.

On Jul, 11, 2026

13,708 people reported to have side effects when taking Emend.
Among them, 88 people (0.64%) have Rash maculo-papular.

Among these 88 people:

How long have people been on Emend when they have Rash maculo-papular? *

What is the gender of people who have Rash maculo-papular when taking Emend? *

female: 48.28 %
male: 51.72 %

What is the age of people who have Rash maculo-papular when taking Emend? *

What are other drugs people take besides Emend? *

What are other side effects people have besides Rash maculo-papular? *

Itching: 25 people, 28.41%
Fever: 22 people, 25.00%
Rashes (redness): 20 people, 22.73%
Diarrhea: 6 people, 6.82%
Mucosal Inflammation (infection of mucous membrane): 5 people, 5.68%
Hepatocellular Injury (liver injury): 4 people, 4.55%
Eosinophilia (eosinophil count in the peripheral blood exceeds): 4 people, 4.55%
Skin Exfoliation (removal of the oldest dead skin cells): 4 people, 4.55%
Rash Papular (redness with papule): 4 people, 4.55%
Dermatitis Bullous (inflammation of the skin characterized by the presence of bullae which are filled with fluid): 3 people, 3.41%

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 14 people, 15.91%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 10 people, 11.36%
Nausea And Vomiting: 10 people, 11.36%
Neoplasm Malignant (cancer tumour): 10 people, 11.36%
Ovarian Cancer (cancer of ovary): 9 people, 10.23%
Swallowing Pain Or Burning: 8 people, 9.09%
Oesophageal Carcinoma (cancer tumour of oesophagus): 8 people, 9.09%
Hodgkin's Disease Stage Iv (cancer originating from white blood cells - stage iv): 6 people, 6.82%
Oral Fungal Infection: 6 people, 6.82%
High Blood Pressure: 5 people, 5.68%

* Approximation only. Some reports may have incomplete information.

Do you take Emend and have Rash maculo-papular?

- Check whether Rash maculo-papular is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Emend:

Emend (13,741 reports)

Browse all side effects of Emend:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rash maculo-papular:

Rash maculo-papular (1,245 drugs)

Browse all the conditions that are associated with Rash maculo-papular:

Rash maculo-papular (1,534 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on aprepitant (the active ingredients of Emend) and Emend (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.